Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)

Exclusion Criteria

• •If a patient has any of the following conditions should not be included in this study:
• •1. Had been treated with PI3K inhibitor or EZH2 inhibitor or EZH1/2 inhibitor before enrollment;
• •2. Primary cutaneous T-cell lymphoma;
• •3. History of other primary aggressive malignancies that are not in remission or in remission for no more than 3 years;
• •4. Involvement of the central nervous system (meninges or brain parenchyma);
• •5. People with a known allergy to any of the drugs in the study
• •6. Participated in other drug clinical trials within 4 weeks before the study began;
• •7. Pregnant or lactating women;
• •8. Active infected persons, except tumor-related B symptom fever;
• •9. Diseases and medical history:
• •1. have multiple factors that affect oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction);
• •2. have a history of psychotropic substance abuse and can not quit or have mental disorders;
• •3. Subjects with any severe and/or uncontrolled medical condition;
• •10. A history of immunodeficiency, including HIV testing positive, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation;
• •11. Other situations deemed unsuitable for inclusion in the study by the researcher.